[MOL] Taxol-prognosis from good to "great" [01114] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Taxol-prognosis from good to "great"



Some good news..love, Joicy

FDA approves Taxol to treat early-stage breast cancer: Drug improves
    a patient's prognosis from good to "great"
    [10/28/99; Cable News Network]

WASHINGTON (CNN) -- The Food and Drug Administration (FDA) has
approved the anti-cancer drug Taxol for the treatment of early
stage breast cancer, after clinical studies showed it helped
prevent relapses of the disease and significantly boosted survival
rates. 

Before the FDA action Tuesday night, Taxol already had been approved
for the treatment of metastatic or advanced breast cancer as
well as lung cancer and ovarian cancer. 

Studies following women for 30 months have shown when Taxol is
combined with surgery to remove the tumor and standard chemotherapy,
there was a 26 percent reduction in death and at 22 percent reduction
in disease recurrence. 

Scientists say Taxol is the first drug in 20 years to improve
the odds for early stage breast cancer. 

"It's a very exciting time that we have a treatment that is so
effective that we're thinking of using it even in good prognosis
patients to take 'good' prognosis and make 'great' prognosis,"
said Dr. Larry Norton, Memorial Sloan-Kettering Cancer Center.

The full article can be found at:

http://www.cnn.com/HEALTH/cancer/9910/27/taxol.approval/index.html

------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------